Visualization and targeted disruption of protein interactions in living cells

Nature Communications

Volumn 4, Issue , 2013, Pages

  Herce, Henry D ^a   Deng, Wen ^b   Helma, Jonas ^b   Leonhardt, Heinrich ^b   Cardoso, M Cristina ^a  

^a DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; NANOBODY; NUTLIN 3; PROTEIN MDM2; PROTEIN P53;

BIOCHEMISTRY; CANCER; DISEASE TREATMENT; PROTEIN; VISUALIZATION;

ARTICLE; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL ASSAY; CELL LINE, TUMOR; CRICETINAE; GENE EXPRESSION; GENES, REPORTER; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; IMIDAZOLES; LUMINESCENT PROTEINS; MICE; MICROSCOPY, FLUORESCENCE; MOLECULAR IMAGING; PIPERAZINES; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTO-ONCOGENE PROTEINS C-MDM2; RECOMBINANT FUSION PROTEINS; SINGLE-DOMAIN ANTIBODIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84886668282     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3660     Document Type: Article

References (37)

1. Fields, S. & Song, O. A novel genetic system to detect protein-protein interactions. Nature 340, 245-246 (1989). (Pubitemid 19171591)
2. Cremazy, F. G. et al. Imaging in situ protein-DNA interactions in the cell nucleus using FRET-FLIM. Exp. Cell. Res. 309, 390-396 (2005). (Pubitemid 41317362)
3. Tsuganezawa, K. et al. A fluorescent-based high-throughput screening assay for small molecules that inhibit the interaction of MdmX with p53. J. Biomol. Screen. 18, 191-198 (2013).
4. Kirchhofer, A. et al. Modulation of protein properties in living cells using nanobodies. Nat. Struct. Mol. Biol. 17, 133-138 (2010).
5. Montes de Oca Luna, R.,Wagner, D. S. & Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203-206 (1995).
6. Jones, S. N., Roe, A. E., Donehower, L. A. & Bradley, A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378, 206-208 (1995).
7. Lane, D. How cells choose to die. Nature 414, 27 (2001).
8. Vousden, K. H. Activation of the p53 tumor suppressor protein. Biochim. Biophys. Acta. 160247-59, 2002.
9. Momand, J., Jung, D., Wilczynski, S. & Niland, J. The MDM2 gene amplification database. Nucleic Acids Res. 26, 3453-3459 (1998). (Pubitemid 28347214)
10. Bond, G. L. et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119, 591-602 (2004). (Pubitemid 39535748)
11. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L. & Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358, 80-83 (1992).
12. Zhou, M. et al. Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia 14, 61-67 (2000). (Pubitemid 30068374)
13. Shimada, H. et al. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sci. 97, 554-561 (2006). (Pubitemid 43811599)
14. Cheok, C. F., Verma, C. S., Baselga, J. & Lane, D. P. Translating p53 into the clinic. Nat. Rev. Clin. Oncol. 8, 25-37 (2011).
15. Tsukamoto, T. et al. Visualization of gene activity in living cells. Nat. Cell. Biol. 2, 871-878 (2000).
16. Arkin, M. R. & Wells, J. A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug. Discov. 3, 301-317 (2004). (Pubitemid 38499758)
17. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004). (Pubitemid 38174664)
18. Issaeva, N. et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10, 1321-1328 (2004). (Pubitemid 40022713)
19. Krajewski, M., Ozdowy, P., DSilva, L., Rothweiler, U. & Holak, T. A. NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat. Med. 11, 1135-1136 (2005). (Pubitemid 43093648)
20. Bottger, V. et al. Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 18, 189-199 (1999). (Pubitemid 29060593)
21. Li, C. et al. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions. J. Mol. Biol. 398, 200-213 (2010).
22. Hu, B., Gilkes, D. M., Farooqi, B., Sebti, S. M. & Chen, J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J. Biol. Chem. 281, 33030-33035 (2006). (Pubitemid 46036685)
23. Tunnemann, G. et al. Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. FASEB J. 20, 1775-178 (2006).
24. Herce, H. D. & Garcia, A. E. Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. Proc. Natl Acad. Sci. USA 104, 20805-20810 (2007).
25. Herce, H. D. et al. Arginine-rich peptides destabilize the plasma membrane, consistent with a pore formation translocation mechanism of cell-penetrating peptides. Biophys. J. 97, 1917-1925 (2009).
26. Ter-Avetisyan, G. et al. Cell entry of arginine-rich peptides is independent of endocytosis. J. Biol. Chem. 284, 3370-3378 (2009).
27. Lattig-Tunnemann, G. et al. Backbone rigidity and static presentation of guanidinium groups increases cellular uptake of arginine-rich cell-penetrating peptides. Nat. Commun. 2, 453 (2011).
28. Nan, X., Campoy, F. J. & Bird, A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88, 471-481 (1997). (Pubitemid 27154412)
29. Brero, A. et al. Methyl CpG-binding proteins induce large-scale chromatin reorganization during terminal differentiation. J. Cell. Biol. 169, 733-743 (2005). (Pubitemid 41002879)
30. Karas, M. & Hillenkamp, F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal. Chem. 60, 2299-2301 (1988).
31. Rothbauer, U. et al. A versatile nanotrap for biochemical and functional studies with fluorescent fusion proteins. Mol. Cell. Proteomics. 7, 282-289 (2008). (Pubitemid 351298442)
32. Rothbauer, U. et al. Targeting and tracing antigens in live cells with fluorescent nanobodies. Nat. Methods 3, 887-889 (2006). (Pubitemid 44614722)
33. Boyd, S. D., Tsai, K. Y. & Jacks, T. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat. Cell. Biol. 2, 563-568 (2000).
34. Zolghadr, K. et al. A fluorescent two-hybrid assay for direct visualization of protein interactions in living cells. Mol. Cell. Proteom. 7, 2279-2287 (2008).
35. Yaffe, D. & Saxel, O. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 270, 725-727 (1977). (Pubitemid 8239246)
36. Ponten, J. & Saksela, E. Two established in vitro cell lines from human mesenchymal tumours. Int. J. Cancer. 2, 434-447 (1967).
37. Scherer, W. F., Syverton, J. T. & Gey, G. O. Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J. Exp. Med. 97, 695-710 (1953).